FULC Q1 2023 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$295,000-88.6% YoY

Gross Profit

-$16M-5566.1% margin

Operating Income

-$28M-9471.2% margin

Net Income

-$25M-8399.7% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

-56.9%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$321M

Total Liabilities

$25M

Stockholders' Equity

$296M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$295,000	$3M	-88.6%
Gross Profit	-$16M	-$15M	-7.7%
Operating Income	-$28M	-$26M	-7.5%
Net Income	-$25M	-$26M	+4.4%